SummaryAcute graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following bone marrow transplantation, and early detection is important to allow effective therapy. Since the presence of apoptotic keratinocytes (dyskeratotic bodies) has been suggested as a useful diagnostic criterion for GVHD, attention has focused on the use of the TUNEL assay to detect apoptosis in clinical specimens. We reviewed clinical specimens upon which TUNEL had been performed for possible artifacts that might interfere with accurate evaluation for GVHD. Several distinct types of artifact were found and could be re-created in experimental systems. Artifacts in TUNEL staining generally resulted from the lack of specificity of this reaction for apoptotic cell death. Artifacts were found resulting from inadequate fixation, over-exposure of the TUNEL reaction, and proximity to the section edge. In addition, a novel artifact, apparently resulting from DNA shearing during the sectioning process, was noted and confirmed using confocal microscopy of experimental specimens. The TUNEL assay must therefore must be interpreted with caution in the clinical setting. In our laboratory, we consider TUNEL-positive cells as apoptotic only when accompanied by apoptotic morphology. Although these criteria clearly miss some cells in the early stages of apoptosis, they provide the highest specificity for apoptotic cell death.Key words: TUNEL, apoptosis, graft-versus-host, artifact, laser confocal scanning microscopy Abbreviations: LCSM, laser confocal scanning microscopy; GVHD, graftversus-host disease; TUNEL, Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling.
Accepted 20 February 2000Acute graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality following bone marrow transplantation (BMT). The pathology of GVHD appears to be multifactorial in origin, resulting from both a direct attack upon recipient tissues by immunocompetent cells from the donor as well as derangements of immune regulatory mechanisms with release of inflammatory cytokines (the so-called "cytokine storm"). These mechanisms most likely work together to cause the pathology of GVHD, which is most pronounced in the skin, GI tract, and liver.GVHD is treated most effectively when detected early, and in most institutions early diagnosis is based on skin biopsy. Unfortunately, the histopathological features of GVHD overlap with other skin pathology frequently seen in BMT recipients, such as drug reactions or alterations secondary to pre-transplant conditioning regimens. Among the criteria useful to distinguish GVHD from these processes, some authors have focused on the presence of "dyskeratotic bodies". We and others have shown that the presence of such bodies, together with other findings such as an activated lymphomonocytic infiltrate, supports the diagnosis of GVHD.1-3 With the recent realisation that these dyskeratotic bodies actually represent apoptotic keratinocytes, 4,5 attention has focused on me...